Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis
Research output: Contribution to journal › Journal article › Research › peer-review
Interferon beta is the first-line treatment for relapsing-remitting multiple sclerosis, but the drug can induce neutralising antibodies against itself, which might reduce effectiveness. We aimed to assess the clinical effect of neutralising antibodies.
| Original language | English |
|---|---|
| Journal | Lancet |
| Volume | 362 |
| Issue number | 9391 |
| Pages (from-to) | 1184-91 |
| Number of pages | 8 |
| ISSN | 0140-6736 |
| DOIs | |
| Publication status | Published - 11 Oct 2003 |
ID: 34102049